In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing therapies for viral infections, cancer, and genetic conditions. What happens to mRNA innovation when funding dries up? This three-part series explores how reductions in funding could impact mRNA technology, affecting innovation, research and future therapies.

Part one: The domino effect of cutting mRNA vaccine research

Part two: Animosity toward mRNA COVID vaccines puts basic science at risk

Part three: Cancer vaccines face collateral damage of mRNA funding cuts